Effect of exacerbations on lung density in alpha-1 antitrypsin deficiency: Subgroup analysis of the RAPID trial programme
C. Strange (Charleston, United States of America), N. McElvaney (Dublin, Ireland), C. Vogelmeier (Marburg, Germany), M. Fries (King of Prussia, United States of America), J. Shah (King of Prussia, United States of America), A. Shebl (Marburg, Germany), O. Vit (Bern, Switzerland), M. Wencker (Loerzweiler, Germany), K. Chapman (Toronto, Canada)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Session: COPD phenotypes: a1 antitrypsin deficiency and beyond
Session type: Poster Discussion
Number: 568
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Strange (Charleston, United States of America), N. McElvaney (Dublin, Ireland), C. Vogelmeier (Marburg, Germany), M. Fries (King of Prussia, United States of America), J. Shah (King of Prussia, United States of America), A. Shebl (Marburg, Germany), O. Vit (Bern, Switzerland), M. Wencker (Loerzweiler, Germany), K. Chapman (Toronto, Canada). Effect of exacerbations on lung density in alpha-1 antitrypsin deficiency: Subgroup analysis of the RAPID trial programme. 568
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: